How Long-Acting Injectables Are Utilized in Pulmonary Arterial Hypertension Pharmaceutical Development
At Oakwood Labs, we’re dedicated to providing alternative solutions to drug delivery and development. This includes our ongoing work creating long-acting injectables for treating pulmonary arterial hypertension.
For those interested in learning more about the specific strides we’ve made within this sector, as well as the opportunity to partner with us, read on or contact our team today.
Then and Now: A Brief History of Pulmonary Arterial Hypertension Drug Development
The introduction of Epoprostenol in 1995 marked the first true breakthrough in pulmonary arterial hypertension (PAH) treatment, as this medication was able to show the potential to target the prostacyclin pathway. Following this development, individuals began further research into other potential treatment options to help patients suffering from PAH.
It was not until 2001 that the first oral therapy, Bosentan, was approved and released to the public. Since then, 12 additional medications have been approved by the FDA to treat PAH, such as soluble guanylate cyclase (sGC) stimulators, endothelin receptor blockers (ERBs), and phosphodiesterase-5 (PDE-5) inhibitors, to name a few.
Additionally, there are a few current trends in the advancement of pulmonary arterial hypertension pharmaceutical development, including those focused on:
- Combination therapies
- Targeted therapies
- Delivery methods
About Our Work Creating Long-Acting Injectables for Treating Pulmonary Arterial Hypertension
The team at Oakwood Labs has used its advanced technology to create injectables for treating pulmonary arterial hypertension. Though most of the formulations that are currently on the market for PAH treatment are mainly oral medications, the use of LAIs can come with several advantages, such as a decrease in the amount of drug administered to the patient, less frequent doses, and more.
Partner with Oakwood Labs
In order to further develop our cardiology program, Oakwood Labs is looking for an external partner to fulfill the responsibilities of the role. This includes managing phases 1–3 of clinical trials, funding development activities, and helping with ongoing commercialization and registration efforts.
For more information on the details of the position, please reach out to our team directly, as we would be happy to supply you with additional information about the development work to date, market opportunity, and estimated financial projections.
FAQs About Pulmonary Arterial Hypertension LAI Development
What are the major benefits of an LAI in cardiovascular treatments?
Pulmonary arterial hypertension (PAH) is a rare, progressive disease that causes high blood pressure in the arteries of the lungs. Symptoms include shortness of breath, chest pain, and increased heartbeat.
LAI treatments in this area focus on vasodilators and platelet aggregation inhibitors. They work by relaxing blood vessels, including those in the lungs, and improving blood flow.
What are the current barriers to an LAI entering this particular space?
The barriers to entry for the LAI space are very high. You need to have a proven technology capable of delivering the right amount of the drug within a given therapeutic window. Plus, you need an FDA-approved GMP facility to manufacture the product, as well as a high level of expertise to understand, develop, and validate the process.
Oakwood Labs has all of these capabilities and over 25 years of experience within this field.
What sets Oakwood Labs apart from others in the development of LAIs to treat PAH and other cardiovascular issues?
Our team of experts has used its technology to develop formulations focused on treating pulmonary arterial hypertension with a release duration of one month. Current treatments, which mostly focus on oral medications, work in different ways but ultimately attempt to decrease symptom severity and increase exercise capacity.
The use of an LAI product would offer benefits similar to other therapeutic areas including reduction in the total amount of drug administered to the patient, as well as less frequent doses.
Reach Out to Us
If you have any additional questions about our continued work in pulmonary arterial hypertension drug development, or if you’re looking to partner with us, please contact us today.
- How Long-Acting Injectables Are Utilized in Pulmonary Arterial Hypertension Pharmaceutical Development - March 5, 2025
- The Role of Long-Acting Injectables in Acromegaly and Carcinoid Tumor Pharmaceutical Treatment for Endocrinology - February 5, 2025
- Opioid Use Disorder: Developing Long-Acting Injectables for Treatment - November 5, 2024